

- 3 **Mnohočetný myelom**
prof. MUDr. Ivan Špička, CSc. I. interní klinika 1. LF UK a VFN, Praha
- 3 **Cílená (biologická) léčba a její využití u karcinomu ovaria**
MUDr. Josef Chovanec, Ph.D. Klinika operační onkologie, oddělení Gynekologické onkologie, MOÚ, Brno
- 3 **Karcinom prsu – aktuální standard cílené léčby a perspektivy**
MUDr. Marta Krásenská Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
- 4 **Biologická léčba renálního karcinomu**
doc. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
- 4 **Biologická léčba karcinomu plic**
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN Motol, Praha
- 5 **Kolorektální karcinom – minulost, současnost a novinky v cílené léčbě**
MUDr. Tomáš Svoboda, Ph.D. Komplexní onkologické centrum FN, Plzeň
- 5 **Everolimus pro léčbu gastrointestinálních a plicních neuroendokrinních nádorů – výsledky klinické studie III. fáze RADIANT-4**
MUDr. Jiří Tomášek, Ph.D. Klinika komplexní onkologické péče MOÚ, Brno
- 5 **Biologická léčba melanomu**
MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika VFN a 1. LF UK, Praha
- 6 **Trametinib a dabrafenib v léčbě metastatického maligního melanomu**
prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN, Plzeň
- 6 **Léčba metastazujícího maligního melanomu kombinací dabrafenibu a trametinibu ve specifickém léčebném programu – kazuistika**
MUDr. Ivona Mrázová, MBA Onkologické oddělení Nemocnice České Budějovice, a. s.
- 6 **Léčba metastazujícího maligního melanomu kombinací terapií BRAF/MEK inhibitorem**
MUDr. Jindřich Kopecký, Ph.D. | MUDr. Ondřej Kubeček Klinika onkologie a radioterapie LF a FN, Hradec Králové
- 6 **Cobimetinib – lékový profil**
MUDr. Eugen Kubala Klinika onkologie a radioterapie FN, Hradec Králové
- 7 **Dlouhodobé přežívání pacientky s metastazujícím melanomem při monoterapii vemurafenibem – kazuistika**
MUDr. Ivana Krajsová, MBA | MUDr. Ilona Procházková | MUDr. Taťána Šuková
Dermatovenerologická klinika VFN a 1. LF UK, Praha
- 7 **Pokračování v léčbě vemurafenibem i po progresi onemocnění – kazuistika**
MUDr. Ivana Krajsová, MBA | MUDr. Ondřej Kodet, Ph.D. Dermatovenerologická klinika VFN a 1. LF UK, Praha
- 7 **Biologická léčba – fenomén současnosti**
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 7 **Chronicky nemocný pacient s revmatoidní artritidou a depresí**
MUDr. Richard Köhler Psychiatrická klinika Fakultní nemocnice, Hradec Králové
- 8 **Non-radiografická axiální spondyloartritida – diagnostické možnosti a terapie**
MUDr. Leona Procházková, Ph.D. II. interní klinika – revmatologie FN u sv. Anny, Brno
- 8 **Zkušenosti s golimumabem u axiální spondyloartritidy**
prof. MUDr. Ladislav Šenolt, Ph.D. Revmatologický ústav, Klinika revmatologie 1. LF UK, Praha
- 8 **Biologická léčba secukinumabem**
doc. MUDr. Vojtěch Thon, Ph.D. Ústav klinické imunologie a alergologie LF a RECETOX Přírodovědecké fakulty MU, Brno
- 9 **Imunogenicita a prediktivní faktory selhání biologické terapie u revmatoidní artritidy – zaměřeno na abatacept**
MUDr. Hana Ciferská, Ph.D. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha
- 9 **Dlouhodobá účinnost adalimumabu – kazuistika**
MUDr. Zdeněk Antal Kožní oddělení, ÚVN – Vojenská fakultní nemocnice, Praha; Fakulta vojenského zdravotnictví, Hradec Králové; Univerzita obrany, Brno

- 10 **Těžká forma psoriázy komplikovaná vznikem roztroušené sklerózy, úspěšně léčená ustekinumabem – kazuistika**
MUDr. Jiří Ettlér | MUDr. Spyridon Gkalpakiotis, Ph.D., MBA Dermatovenerologická klinika 3. LF UK a FN KV, Praha
- 10 **Vedolizumab v léčbě ulcerózní kolitidy – kazuistika**
doc. MUDr. Zuzana Zelinková, Ph.D. IBD Centrum, s. r. o, ASSIDUO, Nemocnica sv. Michala, Bratislava
MUDr. Barbora Kadlečková IBD Centrum, s. r. o, ASSIDUO, Bratislava
- 10 **Možnosti biologické léčby u lupusové nefritidy**
prof. MUDr. Romana Ryšavá, CSc. Klinika nefrologie, 1. LF UK a VFN, Praha
- 10 **Rituximab v léčbě nefrotického syndromu**
prof. MUDr. Vladimír Tesař, DrSc. Klinika nefrologie 1. LF UK a VFN, Praha
- 11 **Individualizace léčby u roztroušené sklerózy**
doc. MUDr. Radomír Taláb, CSc. Neurologická klinika LF UK a FN, Plzeň
- 12 **Alemtuzumab v klinické praxi – kazuistika**
MUDr. Eva Meluzínová Neurologická klinika 2. LF UK a FN Motol, Praha

Mnohočetný myelom

prof. MUDr. Ivan Špička, CSc. I. interní klinika 1. LF UK a VFN, Praha

- Boyle, P. – Ferlay, J.: Cancer incidence and mortality in Europe, 2004. *Ann Oncol*, 2005, 16, s. 481–488.
- Attal, M. – Harousseau, J. L. – Stoppa, A. M., et al.: A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. *N Engl J Med*, 1996, 335, s. 91–97.
- Ludwig, H. – Durie, B. – Bolejack, V., et al.: Myeloma in patients under age 50 presents with more favorable features and shows better survival: An analysis of 10,549 patients from the International Myeloma Working Group. *Blood*, 2008, 111, s. 4039–4047.
- Barlogie, B. – Mitchell, A. – van Rhee, F., et al.: Curing myeloma at last: defining criteria and providing the evidence. *Blood*, 2014, 124, s. 3043–3051.
- Harousseau, J. L. – Mathiot, C. – Attal, M., et al.: Velcade/dexamethasone vs. VAD as induction treatment prior to autologous stem cell transplantation in newly diagnosed patients: updated results of the IFM 2005/01 (abstract). *Blood*, 2007, 110, abstrakt 139.
- San Miguel, J. F. – Schlag, R. – Khuageva, N. K., et al.: VISTA Trial Investigators: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. *N Engl J Med*, 2008, 359, s. 906–917.
- McCarthy, P. L. – Owzar, K. – Anderson, K. C., et al.: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (ahsct) for multiple myeloma: CALGB 100104. *Blood*, 2010, 116, abstrakt 37.
- Attal, M. – Lauwers-Cances, V. – Marit, G., et al.: Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. *N Engl J Med*, 2012, 366, s. 1782–1791.
- Palubo, A. – Hajek, R., et al.: Continuous lenalidomide treatment for newly diagnosed multiple myeloma. *N Engl J Med*, 2012, 366, s. 1759–1769.
- Stewart, A. K. – Rajkumar, S. V. – Dimopoulos, M. A., et al.: Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. *N Engl J Med*, 2015, 372, s. 142–152, doi:10.1056/NEJMoa1411321, Epub 6. 12. 2014.
- Dimopoulos, M. A. – Moreau, P. – Palumbo, A., et al.: Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. *Lancet Oncol*, 2016, 17, s. 27–38.
- Dytfeld, D. – Jasieliec, J. – Griffith, K. A., et al.: Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. *Haematologica*, 2014, 99, s. e162–164.
- Lacy, M. Q. – Alred, J. B. – Gertz, M. A., et al.: Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. *Blood*, 2011, 118, s. 2970–2975.
- Mitsiades, C. S. – Davies, F. E. – Laubach, J. P., et al.: Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. *J Clin Oncol*, 2011, 29, s. 1916–1923.
- Palumbo, A.: How to treat an elderly patient: Combination therapy or sequencing. *ASH 2009: Highlights for Patients with Myeloma*. The 51st Annual Meeting of the American Society for Hematology, New Orleans, Louisiana, 2009, s. 5–8.

Cílená (biologická) léčba a její využití u karcinomu ovaria

MUDr. Josef Chovanec, Ph.D.

Klinika operační onkologie, oddělení Gynekologické onkologie, MOÚ, Brno

- Svod: Dušek, L. – Mužík, J. – Kubásek, M., et al.: *Epidemiologie zhoubných nádorů v České republice*. Masarykova univerzita, 2005, dostupné z: <http://www.svod.cz>, vyhledáno 20. 8. 2015.
- Mackenzie, R. – Talhouk, A. – Eshragh, S., et al.: Morphologic and molecular characteristics of mixed epithelial ovarian cancers. *Am J Surg Pathol*, 2015, 39, s. 1548–1557.
- Risch, H. A. – McLaughlin, J. R. – Cole, D. E., et al.: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. *Am J Hum Genet*, 2001, 68, s. 700–710.
- Ramirez, I. – Chon, H. S. – Apte, S. M.: The role of surgery in the management of epithelial ovarian cancer. *Cancer Control*, 2011, 18, s. 22–30.
- du Bois, A. – Reuss, A. – Pujade-Lauraine, E., et al.: Role of surgical outcome as prognostic factor in advance epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. *Cancer*, 2009, 115, s. 1234–1244.
- Burger, R. A., et al.: Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med*, 2011, 365, s. 2473–2483.
- Oza, A. M., et al.: Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. *Lancet Oncol*, 2015, 16, s. 928–936.
- Aghajanian, C., et al.: Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. *Gynecol Oncol*, 2015, 139, s. 10–16.
- Heiss, M. – Murawa, P. – Koralewski, P., et al.: The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. *Int J Cancer*, 2010, 127, s. 2209–2221.
- Halámková, J. – Petráková, K. – Tomásek, J. – Kiss, I.: Specifika ovariálního karcinomu u pacientek s mutací BRCA: léčba karcinomu ovarii inhibitory PARP. *Prakt Gyn*, 2014, 18, s. 54–59.
- Frampton, J. E.: Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer. *BioDrugs*, 2015, 29, s. 143–150.
- Witteveen, P., et al.: Final overall survival results from AURELIA, an open-label randomised phase III trial of chemotherapy with or without bevacizumab for platinum-resistant recurrent ovarian cancer. *ECC*, 2013.
- Kristensen, G., et al.: Effect of bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer with ascites: Analysis of the AURELIA trial. *IGCS*, 2012.

Karcinom prsu – aktuální standard cílené léčby a perspektivy

MUDr. Marta Krásenská Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

- ÚZIS: *Novotvary 2010 ČR*. Dostupné z: www.svod.cz.
- Pusztai, L. – Mazouni, C. – Anderson, K., et al.: Molecular Classification of Breast Cancer: Limitations and Potential. *Oncologist*, 2006, 11, s. 868–877.
- Buzdar, A. U. – Ibrahim, N. K. – Francis, D., et al.: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. *J Clin Oncol*, 2005, 23, s. 3676–3685.
- Gianni, L. – Eiermann, W. – Semiglazov, V., et al.: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. *Lancet*, 2010, 375, s. 377–384.
- Untch, M. – Rezaei, M. – Loibl, S., et al.: Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from the GeparQuattro study. *J Clin Oncol*, 2010, 28, s. 2024–2031.
- Baselga, J. – Bradbury, I. – Eidtmann, H., et al.: Lapatinib with trastuzumab for HER-2 positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. *Lancet*, 2012, 379, s. 633–640.
- Gianni, L. – Pienkowski, T. – Im, YH., et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER-2 positive breast cancer (NeoSphere): a randomised, multicentre, open label, phase 2 trial. *Lancet Oncol*, 2012, 13, s. 25–32.
- Piccatt-Gebhart, M. – Procter, M. – Leyland-Jones, B., et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med*, 2005, 353, s. 1659–1672.
- Romond, E. – Perez, E. A. – Bryant, J., et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med*, 2005, 353, s. 1673–1684.
- Perez, E. A., et al.: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor-2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. *J Clin Oncol*, 2011, 29, s. 3366–3373.
- Slamon, D. J. – Eiermann, W. – Robert, N., et al.: Adjuvant trastuzumab in HER2-positive breast cancer. *N Engl J Med*, 2011, 365, s. 1273–1283.
- Perez, E. A. – Suman, V. J. – Davidson, N. E., et al.: Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. *J Clin Oncol*, 2011, 34, s. 4491–4497.
- Pivot, X. – Romieu, G. – Debled, M., et al.: 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. *Lancet Oncol*, 2013, 14, s. 741–748.
- Ismael, G. – Hegg, R. – Muehlbauer, S., et al.: Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. *Lancet*, 2012, 13, s. 809–818.
- Pivot, X. – Gligorov, J. – Muler, V., et al.: Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PREFHER): an open-label randomised study. *Lancet Oncol*, 2013, 14, s. 962–970.
- Piccatt-Gebhart, M. J. – Holmes, A. H. – Baselga, J., et al.: First results from the phase III ALTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T–L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). *J Clin Oncol*, 2014, 32 (dopl), abstrakt LBA4.
- Baselga, J. – Campone, M. – Piccart, M., et al.: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med*, 2012, 366, s. 520–529.
- Piccatt, M., et al.: Everolimus plus exemestane for hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2. Ústní prezentace, abstrakt LBA1. European Breast Cancer Conference (EBCC-9), 2014, Glasgow, Skotsko.
- Finn, R. S. – Crown, J. P. – Lang, I., et al.: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. *Lancet Oncol*, 2015, 16, s. 25–35.
- Baselga, J. – Cortes, J. – Kim, S. B., et al.: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *N Engl J Med*, 2012, 366, s. 109–119.
- Swain, S. – Kim, S. – Cortes, J., et al.: Final overall survival (OS) analysis

- from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). European Society for Medical Oncology (ESMO), 2014, kongres, abstrakt, 3500.
- 22 Ellis, P – Barrios, CH – Eiermann, W, et al.: Phase III, randomized study of trastuzumab emtansine ± pertuzumab vs trastuzumab + taxane for first-line treatment of HER-2 positive MBC: Primary results from the MARIANNE study. *J Clin Oncol*, 2015, 33 (dopl.), abstrakt 507.
- 23 Verma, S. – Miles, D. – Gianni, L., et al.: Trastuzumab emtansine for HER2 positive advanced breast cancer. *N Engl J Med*, 2012, 367, s. 1783–1791.
- 24 Krop, I. E. – Kim, S. B. – Gonzáles-Martín, A., et al.: Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2014, 15, s. 689–699, Epub květen 2014.
- 25 Extenet study: Chan, A., et al.: SABCS, 2015, abstrakt 55-02.
- 26 Miller, K. – Wang, M. – Galrow, J., et al.: Paclitaxel plus bevacizumab vs. paclitaxel alone for metastatic breast cancer. *N Engl J Med*, 2007, 357, s. 2666–2676.
- 27 O'Shaughnessy, J. – Schwartzberg, L. S. – Danso, M. A., et al.: A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). Program a abstracty z 2011 American Society of Clinical Oncology Annual Meeting, 3.–7. 6. 2011, Chicigo, Illinois, abstrakt 1007.
- 28 Clinical trials – dostupné z: www.clinicaltrials.gov.

Biologická léčba renálního karcinomu

doc. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

- 1 Dušek, L., et al.: Epidemiologie zhoubných nádorů v České republice. Masarykova univerzita, 2005, dostupné z: <http://www.svod.cz>, vyhledáno 7. 1. 2016.
- 2 Zhoubný novotvar ledviny (C64). Modrá kniha České onkologické společnosti ČLS JEP – 21. aktualizace, platná od 1. 9. 2015. Dostupné z: www.links.cz/informace-pro-praxi/modra-kniha/16-zhoubny-novotvar-ledviny-c64/, vyhledáno 20. 1. 2016.
- 3 Motzer, R. J. – Hutson, T. E. – Tomczak, P., et al.: Sunitinib vs. interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med*, 2007, 356, s. 115–124.
- 4 Sternberg, C. N. – Davis, I. D. – Mardiak, J., et al.: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. *J Clin Oncol*, 2010, 28, s. 1061–1068.
- 5 Motzer, R. J., et al.: Pazopanib vs. sunitinib in metastatic renal-cell carcinoma. *N Engl J Med*, 2013, 369, s. 722–731.
- 6 Rini, B. I., et al.: Comparative effectiveness of axitinib vs. sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. *Lancet*, 2011, 378, s. 1931–1939.
- 7 Escudier, B., et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. *N Engl J Med*, 2007, 356, s. 125–134.
- 8 Escudier, B., et al.: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. *Lancet*, 2007, 370, s. 2103–2111.
- 9 Rini, B. I., et al.: Phase III trial of bevacizumab plus interferon alfa vs. interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. *J Clin Oncol*, 2010, 28, s. 2137–2143.
- 10 Choueiri, T. K., et al.: Cabozantinib vs. everolimus in advanced renal-cell carcinoma. *N Engl J Med*, 2015, 373, s. 1814–1823.
- 11 Motzer, R. J., et al.: Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. *The Lancet Oncology*, 2015, 16, s. 1473–1482.
- 12 Hudes, G., et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med*, 2007, 356, s. 2271–2281.
- 13 Motzer, R. J., et al.: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet*, 2008, 372, s. 449–456.
- 14 Motzer, R. J., et al.: Nivolumab vs. everolimus in advanced renal-cell carcinoma. *N Engl J Med*, 2015, 373, s. 1803–1813.

Biologická léčba karcinomu plic

MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN Motol, Praha

- 1 Mok, T. – To, K. F. – Srimuninit, V., et al.: Clinical outcomes of patients with epidermal growth factor receptor (EGFR) mutations in IPASS (Iressa Pan Asia Study) [abstract B9.5]. *J Thorac Oncol*, 2009, 4, dopl. 1, s. S351.
- 2 Zhou, C. – Wu, Y.-L. – Chen, G., et al.: Erlotinib vs. chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol*, 2011, 12, s. 735–742.
- 3 Rosell, R., et al.: Erlotinib vs. standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EORTC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol*, 2012, 13, s. 239–246.
- 4 Yang, J. Ch. H. – Schuler, M. H. – Yamamoto, N., et al.: LUX-Lung 3: A randomized, open-label, phase III study of afatinib vs. pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. *J Clin Oncol*, 2012, 30, dopl., abstrakt LBA7500.
- 5 Park et al.: Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7). *Ann Oncol*, 2015, 26, dopl. 9, abstrakt LBA2.
- 6 Jänne, P. A., et al.: Clinical activity of the mutant selective EGFR Inhibitor AZD9291 in patients (pts) with EGFR inhibitor resistant non-small cell lung cancer (NSCLC). Presentováno na American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 30. 5.–3. 6. 2014. Abstrakt dostupný z: http://abstracts.asco.org/144/AbstView_144_129721.html, vyhledáno 18. 1. 2016.
- 7 Cross, D. A. – Ashton, S. E. – Ghiorghiu, S., et al.: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. *Cancer Discovery*, 2014, 4, s. 1046–1061, Epub 3. 6. 2014.
- 8 Yang, J. C., et al.: AZD9291 in pre-treated T790M positive advanced NSCLC: AURA study Phase II extension cohort. Abstrakt 943. Prezentováno na 16th World Conference on Lung Cancer, 6.–9. 9. 2015, Denver, CO.
- 9 Mitsudomi, T., et al.: AZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 Phase II study. Abstrakt 1406. Prezentováno na 16th World Conference on Lung Cancer, 6.–9. 9. 2015, Denver, CO.
- 10 Pasi, A. J. – Yang, J. Ch. H. – Kim, D.-V., et al.: AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. *New Eng J Med*, 2015, 372, s. 1689–1699, DOI: 10.1056/NEJMoa1411817, publikováno 30. 4. 2015.
- 11 Klak, E. L. – Bang, Y. – Camidge, D. R., et al.: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med*, 2010, 363, s. 1693–1703.
- 12 Dong-Wan, K., et al.: Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. *J Clin Oncol*, 2014, 32, 5s, dopl., abstrakt 8003.
- 13 Zilan, S. – Meining, W. – Ao, Z.: Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance [J]. *Acta Pharmaceutica Sinica B*, 2015, 5, s. 34–37.
- 14 Ajimizu, H. – Kim, Y. H. – Mishima, M.: Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib. *Med Oncol*, 2015, 32, s. 477.
- 15 Gainor, J. F. – Herman, C. A. – Willoughby, K., et al.: Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. *J Thorac Oncol*, 2015, 10, s. 232–236.
- 16 Iacono, D. – Chiari, R. – Metro, G. – Bennati, C., et al.: Future options for ALK-positive non-small cell lung cancer. *Lung Cancer*, 2015, pii. S0169-5002(14)00527–3.
- 17 Thatcher, N. – Hirsch, F. R. – Luft, A. V., et al.: Necitumumab plus gemcitabine and cisplatin vs. gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. *Lancet Oncol*, 2015, 16, s. 763–774, publikováno online 1. 6. 2015.
- 18 Sander, A., et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *NEJM*, 2006, 355, s. 2542–2550.
- 19 Reck, M. – Kaiser, R. – Mellemgaard, A. – Douillard, J. Y., et al.: LUME-Lung 1 Study Group. Docetaxel plus nintedanib vs. docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. *Lancet Oncol*, 2014, 15, s. 143–155, doi: 10.1016/S1470-2045(13)70586-2, Epub 9. 1. 2014.
- 20 Garon, E. B. – Ciuleanu, T. E. – Arrieta, O., et al.: Ramucirumab plus docetaxel vs. placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. *Lancet*, 2014, 384, s. 665–673, publikováno online 2. 6. 2014.
- 21 Seto, T. – Kato, T. – Nishio, M., et al.: Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. *Lancet Oncol*, 2014, doi: 10.1016/S1470-2045(14)70381-X, publikováno online 28. 8. 2014.
- 22 Shaw, A. T. – Kim, T.-W. – Nakagawa, K., et al.: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med*, 2013, 368, s. 2385–2394.
- 23 Solomon, B. J. – Mok, T. – Kim, D. W., et al.: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med*, 2014, 371, s. 2167–2177.

Kolorektální karcinom – minulost, současnost a novinky v cílené léčbě

MUDr. Tomáš Svoboda, Ph.D. Komplexní onkologické centrum FN, Plzeň

- 1 Meta-Analysis Group in Cancer. *J Clin Oncol*, 1998, 16s. 301–308.
- 2 Köhne, C. H., et al.: Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. *J Clin Oncol*, 2003, 21, s. 3721–3728.
- 3 Kishi, Y. – Zorzi, D. – Contreras, C. M., et al.: Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. *Ann Surg Oncol*, 2010, 17, s. 2870–2876.
- 4 ESMO guidelines: *Lower gastrointestinal cancer 2015*, dostupné z: www.esmo.org, vyhledáno 8. 2. 2016.
- 5 Závadová, E. – Špaček, J. – Vočka, M., et al.: Immunoscore a jeho prediktivní hodnota u kolorektálního karcinomu. *Klin Onkol*, 2015, 28, dopl. 4, s. 4582–4585.
- 6 Van Cutsem E. – Tabernero, J. – Lakomy, R., et al.: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. *J Clin Oncol*, 2012, 30, s. 3499–3506.

Everolimus pro léčbu gastrointestinálních a plicních neuroendokrinních nádorů – výsledky klinické studie III. fáze RADIANT-4

MUDr. Jiří Tomášek, Ph.D. Klinika komplexní onkologické péče MOÚ, Brno

- 1 Yao, J. C. – Hassan, M. – Phan, A., et al.: One hundred years after „carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. *J Clin Oncol*, 2008, 26, s. 3063–3072.
- 2 Rinke, A. – Miller, H. H. – Schade-Brittinger, C., et al.: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. *J Clin Oncol*, 2009, 27, s. 4656–4663.
- 3 Caplin, M. E. – Pavel, M. – Ruszniewski, P.: Lanreotide in metastatic enteropancreatic neuroendocrine tumors. *N Engl J Med*, 2014, 371, s. 224–233.
- 4 Yao, J. C. – Fazio, N. – Singh, S., et al.: Everolimus in advanced, non-functional neuroendocrine tumors of lung or gastrointestinal origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, phase 3 RADIANT-4 Study. Abstrakt 5LBA, ESMO @ ECC 2015.
- 5 Yao, J. C. – Fazio, N. – Singh, S., et al.: Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. *Lancet*, 15. 12. 2015, doi:10.1016/S0140-6736(15)00817-X, Epub před tiskem.

Biologická léčba melanomu

MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika VFN a 1. LF UK, Praha

- 1 Hodi, F. S. – O’Day, S. J. – McDermott, D. F., et al.: Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*, 2010, 363, s. 711–723, doi: 10.1056/NEJMoa1003466, Epub 5. 6. 2010.
- 2 Robert, C. – Thomas, L. – Bondarenko, I., et al.: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N Engl J Med*, 2011, 364, s. 2517–2526, doi: 10.1056/NEJMoa1104621, Epub 5. 6. 2011.
- 3 Schadendorf, D. – Hodi, F. S. – Robert, C. – Wolchok, J. D., et al.: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. *J Clin Oncol*, 2015, doi:10.1200/JCO.2014.56.2736.
- 4 Topalian, S. L. – Sznol, M. – McDermott, D. F., et al.: Survival durable tumor remission and long term safety in patients with advanced melanoma receiving nivolumab. *J Clin Oncol*, 2014, 32, s. 1020–1030.
- 5 Robert, C. – Long, G. V. – Brady, V., et al.: Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med*, 2015, 372, s. 320–330.
- 6 Robert, C. – Ribas, A. – Wolchok, J. D., et al.: Anti-programmed death receptor-1 treatment with pembrolizumab in ipilimumab-erefractory advanced melanoma: a randomized dose-comparison cohort of phase 1 trial. *Lancet*, 2014, 384, s. 1109–1117.
- 7 Vennepureddy, A. – Thumallapally, N. – Nehru, M. V., et al.: Novel drugs and combination therapies for the treatment of metastatic melanoma. *J Clin Med Res*, 2016, 8, s. 63–75.
- 8 Robert, C. – Schachter, J. – Long, G. V., et al.: Pembrolizumab versus ipilimumab in advanced melanoma. *N Engl J Med*, 2015, 372, s. 2521–2532.
- 9 Wolchok, J. D. – Kluger, H. – Callahan, M. K., et al.: Nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med*, 2013, 365, s. 122–133.
- 10 Postow, M. A. – Chesney, J. – Pavlick, A. C., et al.: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. *N Engl J Med*, 2015, 372, s. 2006–2017.
- 11 Larkin, J. – Chiarion-Sileni, V. – Gonzales, R., et al.: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *N Engl J Med*, 2015, 373, s. 23–34.
- 12 Chapman, P. B. – Hauschild, A. – Robert, C., et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med*, 2011, 364, s. 2507–2516.
- 13 Hauschild, A. – Grob, J. – Demidov, L. V., et al.: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre open-label phase 3 randomized controlled trial. *Lancet*, 2012, 380, s. 358–365.
- 14 Flaherty, K. T. – Robert, C. – Hersey, P., et al.: Improved survival with MEK inhibition in BRAF mutated melanoma. *N Engl J Med*, 2012, 367, s. 107–114.
- 15 Long, G. V. – Stroyakovskiy, D. – Gogas, H., et al.: Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. *N Engl J Med*, 2014, s. 1877–1888.
- 16 Long, V. – Stroyakovskiy, D. – Gogas, H., et al.: Dabrafenib and trametinib versus dabrafenib and placebo for Val600 Braf mutant melanoma: a multicentre, double-blind, phase 3 randomized controlled trial. *Lancet*, 2015, 386, s. 444–451.
- 17 Larkin, J. – Ascierto, P. A. – Dréno, B., et al.: Combined vemurafenib and trametinib in BRAF mutated melanoma. *N Engl J Med*, 2014, 371, s. 1867–1876.

Trametinib a dabrafenib v léčbě metastatického maligního melanomu

prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN, Plzeň

- 1 American Cancer Society: Melanoma Skin Cancer. Dostupné z: www.cancer.org/acs/groups/cid/documents/webcontent/003120-pdfr.pdf, vyhledáno 26. 8. 2015.
- 2 Long, G. V. – Stroyakovskiy, D. – Gogas, H., et al.: Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *Lancet*, 2015, publikováno online 30. 5. 2015.
- 3 Robert, C. – Karaszewska, B. – Schachter, J., et al.: Improved overall survival in melanoma with combined dabrafenib and trametinib. *N Engl J Med*, 2015, 372, s. 30–39.
- 4 National Cancer Institute: A Snapshot of Melanoma. Dostupné z: <http://www.cancer.gov/research/progress/snapshots/melanoma>, vyhledáno 26. 8. 2015.
- 5 Long, G. V. – Stroyakovskiy, D. – Gogas, H., et al.: Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. *Lancet*, 2015, 386, s. 444–451.
- 6 Long, G. V., et al.: ASCO 2015. *Lancet*, 2015, 386, s. 444–451.
- 7 Robert, C., et al.: Two-year estimate of overall survival in COMBI-v, a randomized, open-label, phase 3 study comparing the combination of dabrafenib and trametinib vs vemurafenib as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma, 18th ESMO – 40th ESMO 2015, abstrakt 3301, dostupné online z <http://www.esmo.org>.

Léčba metastazujícího maligního melanomu kombinací dabrafenibu a trametinibu ve specifickém léčebném programu – kazuistika

MUDr. Ivona Mrázová, MBA Onkologické oddělení Nemocnice České Budějovice, a. s.

- 1 Aktuální léčba maligního melanomu. *Farmakoterapie*, 2015.
- 2 Long, G. V.: *Lancet Oncol*, 2015, 336, s. 444–451.
- 3 Long, G. V. – Menzies, A. M. – Nagrial, A. M., et al.: Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. *J Clin Oncol*, 2011, 29, s. 1239–1246.
- 4 Hauschild, A. – Grob, J. J. – Demidov, L. V., et al.: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomized controlled trial. *Lancet*, 2012, 380, s. 358–365.
- 5 Hauschild, A. – Grob, J. – Demidov, L., et al.: An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). *J Clin Oncol*, 2013, 31 (dopl.), abstrakt 9013.
- 6 Flaherty, K. T. – Robert, C. – Hensley, P., et al.: METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. *N Engl J Med*, 2012, 367, s. 107–114.
- 7 Flaherty, K. T. – Infante, J. R. – Daud, A., et al.: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *N Engl J Med*, 2012, 376, s. 1694–1703.
- 8 Long, G. V. – Stroyakovskiy, D. – Gogas, H., et al.: Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. *N Engl J Med*, 2014, 371, s. 1877–1888.
- 9 Robert, C. – Karaszewska, B. – Schachter, J., et al.: Improved overall survival in melanoma with combined dabrafenib and trametinib. *N Engl J Med*, 2015, 372, s. 30–39.
- 10 Stenger, M.: Trametinib and dabrafenib in combination for unresectable or metastatic melanoma with BRAF V600E or V600K mutations. *ASCO Post*, 2014, 5, vyd. 3.

Léčba metastazujícího maligního melanomu kombinací terapií BRAF/MEK inhibitory

MUDr. Jindřich Kopecný, Ph.D. | MUDr. Ondřej Kubeček
Klinika onkologie a radioterapie LF a FN, Hradec Králové

- 1 Cheby, Y. – Zhang, G. – Li, G.: Targeting MAPK pathway in melanoma therapy. *Cancer Metastasis Rev*, 2013, 32, s. 567–584.
- 2 Moreau, S. – Saiag, P. – Aegerter, P., et al.: Prognostic value of BRAF (V600) mutations in melanoma patients after resection of metastatic lymph nodes. *Ann Surg Oncol*, 2012, 19, s. 4314–4321.
- 3 Hauschild, A. – Grob, J. J. – Demidov, L. V., et al.: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet*, 2012, 380, s. 358–365.
- 4 McArthur, G. A. – Chapman, P. B. – Robert, C., et al.: Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. *Lancet Oncol*, 2014, 15, s. 323–332.
- 5 Chapman, P. B.: Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation. *Am Soc Clin Oncol Educ Book*, 2013, doi: 10.1200/EdBook_AM.2013.33.e80.
- 6 Flaherty, K. T. – Infante, J. R. – Daud, A., et al.: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *N Engl J Med*, 2012, 367, s. 1694–1703.
- 7 Long, G. V. – Stroyakovskiy, D. – Gogas, H., et al.: Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *Lancet*, 2015, 386, s. 444–451.
- 8 Schadendorf, D. – Amonkar, M. M. – Stroyakovskiy, D., et al.: Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. *Eur J Cancer*, 2015, 51, s. 833–840.
- 9 Kopecný, J. – Kubeček, O. – Trojanová, P., et al.: Adverse effects of modern treatment of malignant melanoma and their treatment/management. *Klin Onkol*, 2014, 27, s. 393–400.
- 10 Flaherty, K. T. – Robert, C. – Hersey, P., et al.: Improved survival with MEK inhibition in BRAF-mutated melanoma. *N Engl J Med*, 2012, 367, s. 107–114.

Cobimetinib – lékový profil

MUDr. Eugen Kubala Klinika onkologie a radioterapie FN, Hradec Králové

- 1 Pui-Kei, W. – Jong-In, P.: MEK1/2 Inhibitors: molecular activity and resistance mechanisms. *Semin Oncol*, 2015, 42, s. 849–862.
- 2 Wasyluk, B. – Haman, J. – Gutierrez-Hartmann, A.: Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. *Trends Biochem Sci*, 1998, 23, s. 213–216.
- 3 Kolch, W. – Heidecker, G. – Lloyd, P. – Rapp, U. R.: RAF-1 protein kinase is required for growth of induced NIH/3T3 cells. *Nature*, 1991, 349, s. 426–428.
- 4 Moodie, S. A. – Willumsen, B. M. – Weber, M. J., et al.: Complexes of Ras. GTP with RAF-1 and mitogen-activated protein kinase kinase. *Science*, 1993, 260, s. 1658–1661.
- 5 Marshall, C. J.: Cell signalling. RAF gets it together. *Nature*, 1996, 383, s. 127–128.
- 6 Hagemann, C. – Rapp, U. R.: Isotype-specific functions of RAF kinases. *Exp Cell Res*, 1999, 253, s. 34–46.
- 7 Roskoski, R. Jr.: ERK1/2 MAP kinases: structure, function, and regulation. *Pharmacol Res*, 2012, 66, s. 105–143.
- 8 Hoshino, R. – Chatani, Y. – Yamori, T., et al.: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. *Oncogene*, 1999, 18, s. 813–822.
- 9 Ohren, J. F. – Chen, H. – Pavlovsky, A., et al.: Structures of human MAP kinase Kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. *Nat Struct Mol Biol*, 2004, 11, s. 1192–1197.
- 10 Friday, B. B. – Yu, C. – Dy, G. K., et al.: BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and RAF proteins. *Cancer Res*, 2008, 68, s. 6145–6153.

- 11 Hostino, R. – Chatani, Y. – Yamori, T., et al.: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. *Oncogene*, 1999, 18, s. 813–822.
- 12 Shapiro, G. – Klak, J. M. – Clary, L., et al.: Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: a first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors. *J Clin Oncol*, 2011, 29, dopl., abstrakt 3005.
- 13 LoRusso, P. – Shapiro, G. – Pandya, S.: A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors. *J Clin Oncol*, 2012, 30, dopl., abstrakt 2566.
- 14 Gonzalez, R. – Ribas, A. – Daud, A.: Phase Ib study of vemurafenib in combination with the MEK inhibitor, GDC0973, in patients (pts) with unresectable or metastatic BRAF V600 mutated melanoma (BRIM 7). Kongres ESMO 2012, Vídeň, 28. 9.–2. 10. 2012, abstrakt LBA28.
- 15 Dinias, A., et al.: Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase Ib study. *Lancet Oncol*, 2014, 15, s. 954–965.
- 16 Larkin, J., et al.: Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. *N Engl J Med*, 2014, 371, s. 1867–1876.
- 17 Pavlick, A. – Dinias, A. – Gonzalez, R.: Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma. *J Clin Oncol*, 2015, 33, dopl., abstrakt 9020.
- 18 Larkin, J. – Yan, Y. – McArthur, G. A., et al.: Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. *J Clin Oncol*, 2015, 33, dopl., abstrakt 9006.
- 19 Atkinson, V. – Larkin, J. – McArthur, G. A., et al.: Improved overall survival (OS) with cobimetinib (COBI) + vemurafenib (V) in advanced BRAF-mutated melanoma and biomarker correlates of efficacy. SMR 2015, kongres LBA.

Dlouhodobé přežívání pacientky s metastazujícím melanomem při monoterapii vemurafenibem – kazuistika

MUDr. Ivana Krajsová, MBA | MUDr. Ilona Procházková | MUDr. Taťána Šuková
Dermatovenerologická klinika VFN a 1. LF UK, Praha

- 1 Flaherty, T. K. – Sosman, A. J. – Atkins, M. B.: New options and new questions: How to select and sequence therapies for patients with metastatic melanoma. *Am Soc Clin Oncol Educ Book*, 2012, s. 524–530.
- 2 Larkin, J. – Ascierto, P. A. – Dréno, B., et al.: Combined vemurafenib and cobimetinib in BRAF mutated melanoma. *NEJM*, 2014, 371, s. 1867–1876.
- 3 Zahnreich, S. – Mayer, A. – Loquai, C., et al.: Radiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilities. *Future Oncol*, 2016, 12, s. 95–106.
- 4 Puzanov, I. – Amaravadi, R. V. – McArthur, G. A., et al.: Long-term outcome in BRAF V600E melanoma patients treated with vemurafenib: patterns of disease progression and clinical management of limited progression. *EJC*, 2015, 51, s. 1435–1443.

Pokračování v léčbě vemurafenibem i po progresi onemocnění – kazuistika

MUDr. Ivana Krajsová, MBA | MUDr. Ondřej Kodet, Ph.D.
Dermatovenerologická klinika VFN a 1. LF UK, Praha

- 1 McArthur, G. A. – Chapman, P. B. – Robert, C., et al.: Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation positive melanoma (BRIM-3): extended follow up of phase 3, randomized, open label study. *Lancet Oncol*, 2014, 15, s. 323–332.
- 2 Schoitens, A. – Geukes Foppen, M. H. – Blank, C. U., et al.: Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression. *EJC*, 2015, 51, s. 642–652.
- 3 Chan, M. K. – Haydu, E. L. – Long, G. V., et al.: The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition. *Cancer*, 2014, 120, s. 3142–3153.
- 4 Grimaldi, A. M. – Simeone, E. – Palla, M., et al.: Vemurafenib beyond progression in a patient with metastatic melanoma: a case report. *Anticancer Drugs*, 2015, 4, s. 464–468.

Biologická léčba – fenomén současnosti

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 Lambert, R. G. – Bakker, P. A. C. – van der Heide, D., et al.: Defining active sacroiliitis on MR for classification of axial spondyloarthritis: update by the ASAS MR working group. *Ann Rheum Dis*, 2016, doi:10.1136/annrheumdis-2015-208642.
- 2 Baeten, D. – Sieper, J. – Braun, J., et al.: Secukinumab, an Interleukin-17 inhibitor in ankylosing spondylitis. *N Engl J Med*, 2015, 373, s. 2534–2548.
- 3 McInnes, I. B. – Mease, P. J. – Kirkham, B., et al.: Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE II): a randomised, double-blind, placebo-controlled, phase 3 trial. Publikováno online 29. 6. 2015, [http://dx.doi.org/10.1016/S0140-6736\(15\)61134-5](http://dx.doi.org/10.1016/S0140-6736(15)61134-5).
- 4 Gossec, L. – Smolen, J. S. – Ramiro, S., et al.: European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. *Ann Rheum Dis*, 2016, 75, s. 499–510.

Chronicky nemocný pacient s revmatoidní artritidou a depresí

MUDr. Richard Köhler Psychiatrická klinika Fakultní nemocnice, Hradec Králové

- 1 Anderson G., et al.: Increased IL-6 trans-signaling in depression: focus on the tryptophan catabolite pathway, melatonin and neuroprogression. *Pharmacological Reports*, 2013, 65, s. 1647–1654.
- 2 Ang, D. C., et al.: Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. *Journal of Rheumatology*, 2005, 32, s. 1013–1019.
- 3 Baroš, M. – Novák, T.: Depresivní porucha. In: Seifertová, D. – Praško, J. – Horáček, J. – Höschl, C.: *Postupy v léčbě psychických poruch*. Praha, Academia Medica Pragensis, 2008, s. 103–113.
- 4 Bob, P., et al.: Depression, traumatic stress and interleukin-6. *Journal of Affective Disorders*, 2010, 120, s. 231–234.
- 5 Cutolo, M., et al.: Burden of disease in treated rheumatoid arthritis patients: Going beyond the joint. *Seminars in Arthritis and Rheumatism*, 2014, 43, s. 479–488.
- 6 Dickens, C. – Creed F.: The burden of depression in patients with rheumatoid arthritis. *Rheumatology*, 2001, 40, s. 1327–1330.
- 7 Hannestad, J., et al.: The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. *Neuropsychopharmacology*, 2011, 36, s. 2452–2459.
- 8 Hawker, G. A., et al.: A longitudinal study to explain the pain-depression link in older adults with osteoarthritis. *Arthritis Care and Research*, 2011, 63, s. 1382–1390.
- 9 Herman, E., et al.: Poruchy nálady. In: Herman, E. – Praško, J. – Seifertová, D.: *Konziliární psychiatrie*. Praha, Galén, Medical Tribune, 2007, s. 79–93.
- 10 Hewlett, S., et al.: Self-management of fatigue in rheumatoid arthritis: a randomised controlled trial of group cognitive-behavioural therapy. *Annals of the Rheumatic Diseases*, 2011, 70, s. 1060–1067.
- 11 Kubera, M., et al.: In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are

- associated to the onset of depression. *Prog Neuropsychopharmacol Biol Psychiatry*, 2011, 35, s. 744–759.
- 12 **Leopard, B. – Maes, M.**: Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. *Neuroscience and Biobehavioral Reviews*, 2012, 36, s. 764–785.
 - 13 **Matcham, F., et al.**: The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. *Rheumatology*, 2013, 52, s. 2136–2148.
 - 14 **O'Brien, S. M., et al.**: Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. *Journal of Psychiatric Research*, 2007, 41, s. 326–331.
 - 15 **Perrot, S., et al.**: Guidelines for use of antidepressants in painful rheumatic conditions. *European Journal of Pain*, 2006, 10, s. 185–192.
 - 16 **Praško, J.**: Diagnostika a léčba psychických poruch při chronické bolesti. In: Herman, E. – Praško, J. – Seifertová, D.: *Konziliární psychiatrie*. Praha, Galén, Medical Tribune, 2007, s. 489–504.
 - 17 **Praško, J., et al.**: Depresivní poruchy. In: Praško, J. – Látalová, K. – Ticháčková, A. – Stárková, L.: *Klinická psychiatrie*. Praha, Tigris, 2011, s. 235–280.
 - 18 **Sansone, R. A. – Sansone, L. A.**: Tramadol: seizures, serotonin syndrome, and coadministered antidepressants. *Psychiatry (Edgemont)*, 2009, 6, s. 17–21.
 - 19 **Stewart, J. C., et al.**: A prospective evaluation of the directionality of the depression-inflammation relationship. *Brain, Behavior, and Immunity*, 2009, 23, s. 936–944.
 - 20 **Valkanova, V., et al.**: CRP, IL-6 and depression: A systematic review and meta-analysis of longitudinal studies. *Journal of Affective Disorders*, 2013, 150, s. 736–744.

Non-radiografická axiální spondyloartritida – diagnostické možnosti a terapie

MUDr. Leona Procházková, Ph.D. II. interní klinika – revmatologie FN u sv. Anny, Brno

- 1 **Rudwaleit, M. – van der Neue, D. – Landewé, R., et al.**: The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis*, 2009, 68, s. 777–783.
- 2 **Stolwijk, C., et al.**: Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. *Rheum Dis Clin North Am*, 2012, 28, s. 441–476.
- 3 **Van Hoveen, L. – Luime, J. – Han, H., et al.**: Identifying axial spondyloarthritis in Dutch primary care patients, ages 20–45 years, with chronic low back pain. *Arthritis Care Res*, 2014, 66, s. 446–453.
- 4 **Poddubnyy, D. – Seper, J.**: Similarities and differences between nonradiographic and radiographic axial spondyloarthritis: a clinical, epidemiological and therapeutic assessment. *Current Opin Rheumatol*, 2014, 26, s. 377–383.
- 5 **Sieper, J. – van der Heijde, D. – Dougados, M., et al.**: Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). *Ann Rheum Dis*, 2013, 72, s. 815–822.
- 6 **Lambert, R. G. W. – Akker, P. A. C. – van der Neue, D., et al.**: Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). *Ann Rheum Dis*, 2013, 72, s. 815–822.
- 7 **Seo, M. R. – Baek, H. L. – Yoon, H. H., et al.**: Delayed diagnosis is linked to worse outcomes and unfavourable treatment responses in patients with axial spondyloarthritis. *Clin Rheumatol*, 2015, 34, s. 1397–1405.
- 8 **van Onna M. – van Tubergen A. – Jurik, A. G., et al.**: Natural course of bone marrow oedema on magnetic resonance imaging of the sacroiliac joints in patients with early inflammatory back pain: a 2-year follow-up study. *Scand J Rheumatol*, 2015, 44, s. 129–134.
- 9 **Callhoff, J. – Sieper, J. – Weiss, A., et al.**: Efficacy of TNF α blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. *Ann Rheum Dis*, 2015, 74, s. 1241–1248.

Zkušenosti s golimumabem u axiální spondyloartritidy

prof. MUDr. Ladislav Šenolt, Ph.D. Revmatologický ústav, Klinika revmatologie 1. LF UK, Praha

- 1 **Braun, J. – Seper, J.**: Ankylosing spondylitis. *Lancet*, 2007, 369, s. 1379–1390.
- 2 **Sieper, J. – van der Heijde, D.**: Review: Nonradiographic axial spondyloarthritis: new definition of an old disease? *Arthritis Rheum*, 2013, 65, s. 543–551.
- 3 **Forejtová, S. – Mann, H. – Štolfa, J. – Vedral, K. – Fenclová, I. – Némethová, D. – Pavelka, K.**: Factors influencing health status and disability of patients with ankylosing spondylitis in the Czech Republic. *Clin Rheumatol*, 2008, 27, s. 1005–1013.
- 4 **Diner, U. – Cakar, E. – Kiralp, M. Z. – Dursun, H.**: Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. *Clin Rheumatol*, 2008, 27, s. 457–462.
- 5 **Rudwaleit, M. – van der Heijde, D. – Landewé, R., et al.**: The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis*, 2009, 68, s. 777–783.
- 6 **Paramarta, J. E. – Baeten, D.**: Spondyloarthritis: from unifying concepts to improved treatment. *Rheumatology (Oxford)*, 2014, 53, s. 1547–1559.
- 7 **Reveille, J. D. – Weisman, M. H.**: The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States. *Am J Med Sci*, 2013, 345, s. 431–436.
- 8 **Strand, V. – Rao, S. A. – Shillington, A. C., et al.**: Prevalence of axial spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis. *Arthritis Care Res (Hoboken)*, 2013, 65, s. 1299–1306.
- 9 **Lambert, R. G. W. – Akker, P. A. C. – van der Heijde, D., et al.**: Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. *Ann Rheum Dis*, 14. 1. 2016.
- 10 **Poddubnyy, D. – Seper, J.**: Radiographic progression in ankylosing spondylitis/axial spondyloarthritis: how fast and how clinically meaningful? *Curr Opin Rheumatol*, 2012, 24, s. 363–369.
- 11 **Pavelka, K. – Mann, H.**: Zánětlivá bolest v zádech – význam při screeningu a diagnostice spondyloartritidy. *Čes Revmatol*, 2014, 3, s. 143–152.
- 12 **Rudwaleit, M. – Khan, M. A. – Seper, J.**: The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? *Arthritis Rheum*, 2005, 52, s. 1000–1008.
- 13 **Arends, S. – Brouwer, E. – van der Veer, E., et al.**: Baseline predictors of response and discontinuation of tumor necrosis factor- α blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. *Arthritis Res Ther*, 2011, 13, s. R94.
- 14 **Šenolt, L. – Mann, H. – Herle, P.**: *Revmatologie – Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře*. Centrum doporučených postupů pro praktické lékaře, 2014.
- 15 **Sieper, J. – Rudwaleit, M.**: Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. *Ann Rheum Dis*, 2005, 64, s. 659–663.
- 16 **Braun, J. – van den Berg, R. – Baraliakos, X., et al.**: 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis*, 2011, 70, s. 896–904.
- 17 **Pavelka, K.**: Doporučení České revmatologické společnosti pro léčbu ankylozující spondylitidy. *Čes Revmatol*, 2012, 1, s. 4–11.
- 18 **Inman, R. D. – Davis, J. C. Jr. – van der Heijde, D., et al.**: Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. *Arthritis Rheum*, 2008, 58, s. 3402–3412.
- 19 **Deodhar, A. – Braun, J. – Inman, R. D., et al.**: Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. *Ann Rheum Dis*, 2015, 74, s. 757–761.
- 20 **Braun, J. – Baraliakos, X. – Hermann, K. G., et al.**: The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. *Ann Rheum Dis*, 2014, 73, s. 1107–1113.
- 21 **Sieper, J. – van der Heijde, D. – Dougados, M., et al.**: A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. *Arthritis Rheumatol*, 2015, 67, s. 2702–2712.
- 22 **van der Linden, S. – Valkenburg, H. A. – Cats, A.**: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum*, 1984, 27, s. 361–368.

Biologická léčba secukinumabem

doc. MUDr. Vojtěch Thon, Ph.D.

Ústav klinické imunologie a alergologie LF a RECETOX Přírodovědecké fakulty MU, Brno

- 1 **Rouvier, E. – Luciani, M. F. – Mattéi, M. G., et al.**: CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. *J Immunol*, 1993, 150, s. 5445–5456.
- 2 **Yao, Z. – Fanslow, W. C. – Seldin, M. F., et al.**: Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. *Immunity*, 1995, 3, s. 811–821.
- 3 **Yao, Z. – Spriggs, M. K. – Derry, J. M., et al.**: Molecular characterization of the human interleukin (IL)-17 receptor. *Cytokine*, 1997, 9, s. 794–800.
- 4 **Lynde, C. W. – Poulin, Y. – Vender, R., et al.**: Interleukin 17A: toward a new understanding of psoriasis pathogenesis. *J Am Acad Dermatol*, 2014, 71, s. 141–150.
- 5 **Roman, M. – Madkan, V. K. – Chiu, M. W.**: Profile of secukinumab in the treatment of psoriasis: current perspectives. *Ther Clin Risk Manag*, 2015, 11, s. 1767–1777.
- 6 **Ouellette, A. J.**: Paneth cells and innate mucosal immunity. *Curr Opin Gastroenterol*, 2010, 26, s. 547–553.
- 7 **Wilson, N. J. – Boniface, K. – Chan, J. R., et al.**: Development, cytokine profile and function of human interleukin 17-producing helper T cells. *Nat Immunol*, 2007, 8, s. 950–957.
- 8 **Durham, L. E. – Kirkham, B. W. – Tasmé, L. S.**: Contribution of the IL-17 pathway to psoriasis and psoriatic arthritis. *Curr Rheumatol Rep*, 2015, 17, s. 55.
- 9 **Hueber, W. – Patel, D. D. – Dryja, T., et al.**: Effects of AIN457, a fully

- human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. *Sci Transl Med*, 2010, 2, s. 52ra72.
- 10 Hueber, W. – Sands, B. E. – Lewitzky, S., et al.: Secukinumab in Crohn's Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. *Gut*, 2012, 61, s. 1693–1700.
 - 11 Langley, R. G. – Elewski, B. E. – Lebwohl, M., et al.: Secukinumab in plaque psoriasis—results of two phase 3 trials. *N Engl J Med*, 2014, 371, s. 326.
 - 12 Paul, C. – Lacour, J. P. – Tedremets, L., et al.: Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). *J Eur Acad Dermatol Venereol*, 2015, 29, s. 1082.
 - 13 Blauvelt, A. – Prinz, J. C. – Gottlieb, A. B., et al.: Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). *Br J Dermatol*, 2015, 172, s. 484.
 - 14 Thaçi, D. – Blauvelt, A. – Reich, K., et al.: Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. *J Am Acad Dermatol*, 2015, 73, s. 400.
 - 15 McInnes, I. B. – Mease, P. J. – Kirkham, B., et al.: FUTURE 2 Study Group. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*, 2015, s. 1137–1146.
 - 16 Mease, P. J. – McInnes, I. B. – Kirkham, B., et al.: FUTURE 1 Study Group. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. *N Engl J Med*, 2015, 373, s. 1329–1339.
 - 17 Baeten, D. – Baraliakos, X. – Braun, J., et al.: Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. *Lancet*, 2013, 382, s. 1705.
 - 18 Baeten, D. – Sieper, J. – Braun, J., et al.: Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. *N Engl J Med*, 2015, 373, s. 2534.
 - 19 Baeten, D. – Blanco, R. – Geusens, P., et al.: Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis in anti-TNF-naïve patients and those previously exposed to anti-TNF therapy: 52-week results from two randomized, double-blind, placebo-controlled phase 3 trials [abstract]. *Arthritis Rheumatol*, 2015, 67, suppl. 10.

Imunogenicitá a prediktivní faktory selhání biologické terapie u revmatoidní artritidy – zaměřeno na abatacept

MUDr. Hana Ciferská, Ph.D. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha

- 1 Pavelka, K. – Vencovský, J., et al.: Doporučení České revmatologické společnosti pro léčbu revmatoidní artritidy. *Česká Revmatologie*, 2010, 4, s. 182–191.
- 2 Smolen, J. S. – Landewé, R. – Breedveld, F. C., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis*, 2014, 73, s. 492–509.
- 3 van Schouwenburg, P. A. – Rispen, T. – Wolbink, G. J.: Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. *Nature Reviews Rheumatology*, 2013, 9, s. 164–172.
- 4 Schiff, M.: Subcutaneous abatacept for the treatment of rheumatoid arthritis. *Rheumatology (Oxford)*, 2013, 52, s. 986–997.
- 5 Vultaggio, A. – Maggi, E. – Matucci, A.: Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. *Curr Opin Allergy Clin Immunol*, 2011, 11, s. 262–268.
- 6 Clarke, J. B.: Mechanisms of adverse drug reactions to biologicals. *Handb Exp Pharmacol*, 2010, 196, s. 453–474.
- 7 Isaacs, J. D. – Cohen, S. B. – Emery, P. E., et al.: Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. *Ann Rheum Dis*, 2013, 72, s. 329–336.
- 8 Piantoni, S. – Kolombo, E. – Tincani, A., et al.: Predictive factors of abatacept therapy discontinuation in patients with rheumatoid arthritis. *Clin Rheumatol*, 2016, 36, s. 1–10.
- 9 Carvalheiro, H. – Duarte, C. – Silva-Cardoso, S., et al.: CD8+ T cell profiles in patients with rheumatoid arthritis and their relationship to disease activity. *Arthritis Rheumatol*, 2015, 67, s. 363–371.
- 10 Airó, P. – Kolombo, E. – Piantoni, S., et al.: CD8+ T cell profiles in patients with rheumatoid arthritis—the effects of costimulation blockade: comment on the article by Carvalheiro et al. *Arthritis Rheumatol*, 2015, 67, s. 2273–2274.
- 11 Gribben, J. G. – Devereux, S. – Thomas, N. S., et al.: Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. 1990. *Lancet*, 335, s. 434–437.
- 12 Felipe, V. – Hawe, A. – Schellekens, H., et al.: Aggregation and immunogenicity of therapeutic proteins. In: Wang, W. – Roberts, C. (Eds): *Aggregation of therapeutic proteins*. John Wiley & Sons Inc., NJ, USA, 2010.
- 13 Jani, M. – Barton, A. – Warren, R. B., et al.: The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. *Rheumatology (Oxford)*, 2014, 53, s. 213–222.
- 14 Orenia™ SPC, dostupné z: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000701/WC500048935.pdf, vyhledáno 22. 2. 2016.
- 15 Iwahashi, M. – Inoue, H. – Matsubara, T., et al.: Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study. *Mod Rheumatol*, 2014, 24, s. 885–891.
- 16 Genovese, M. C. – Covarrubias, A. – Leon, G., et al.: Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. *Arthritis Rheum*, 2011, 63, s. 2854–2864.
- 17 Keystone, E. C. – Kremer, J. M. – Russell, A., et al.: Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. *Ann Rheum Dis*, 2012, 71, s. 857–861.
- 18 Nash, P. – Nayiager, S. – Genovese, M. C., et al.: Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: Results from a phase III, international, multicenter, parallel-arm, open-label study. *Arthritis Care Res*, 2013, 65, s. 718–728.
- 19 Kaine, J. – Gladstein, G. – Strusberg, I., et al.: Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase IIIb ALLOW study). *Ann Rheum Dis*, 2012, 71, s. 38–44.
- 20 Gottenberg, J. E. – Ravada, P. – Bardin, T., et al.: Positivity for RF/anti-CCP is associated with a better response to abatacept: data from the Orenia and Rheumatoid Arthritis (ORA) registry. *Ann Rheum Dis*, 2011, 70, s. 74.
- 21 Lv, Q. – Yin, Y. – Li, X., et al.: The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNF α agent treatment in patients with rheumatoid arthritis: a meta-analysis. *PLoS ONE*, 2014, 9, e89442.
- 22 Nüßlein, H. G. – Alten, R. – Galeazzi, M., et al.: Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. *BMC Musculoskelet Disord*, 2015, 30, s. 176.
- 23 Sokolove, J. – Schiff, M. – Fleischmann, R., et al.: Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. *Ann Rheum Dis*, 2010, 9, 2015.

Dlouhodobá účinnost adalimumabu – kazuistika

MUDr. Zdeněk Antal Kožní oddělení, ÚVN – Vojenská fakultní nemocnice, Praha; Fakulta vojenského zdravotnictví, Hradec Králové; Univerzita obrany, Brno

- 1 Arenberger, P. – Buchtová, L. – Hladovec, J.: Increase of endothelialiaemia in psoriasis. *Acta dermatovenerol*, 1993, 73, s. 35–36.
- 2 Benáková, N.: Trendy v léčbě psoriázy 2006. In: *Dermatovenerologie, dětská dermatologie a korektivní dermatologie 2006/2007. Trendy v medicíně*, 2006, s. 13–19.
- 3 Di Cesare, A. – Di Meglio, P. – Nestle, F. O.: The IL-23/Th 17 axis in the immunopathogenesis of psoriasis. *J Invest Dermatol*, 2009, 129, s. 1339–1350.
- 4 Dubertret, L.: *Psoriasis from clinic to therapy*. Med'com, Paris, 2005, s. 1–24.
- 5 Leonardi, C. L. – Kimball, A. B. – Papp, K. A., et al.: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76 week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). *Lancet*, 2008, 371, s. 1665–1674.
- 6 Lowes, M. A. – Bowcock, A. M. – Krueger, J. G.: Pathogenesis and therapy of psoriasis. *Nature*, 2007, 445, s. 866–873.
- 7 Merle Elloso, M. – Gomez-Angelats, M. – Fourie, A. M.: Targeting the Th 17 pathway in psoriasis. *J Leukoc Biol*, 2012, 92, s. 1187–1197.
- 8 Semrádová, V. – Vašků, V. – Balaščík, D. – Slonková, V.: Kvalita života u pacientů s psoriázou vulgaris I. Vliv terapie na kvalitu života. *Čs Derm*, 2006, 81, s. 153–161.
- 9 Vašků, V.: Celková léčba psoriázy. Referátový výběr z dermatovenerologie 2005. *Speciál II/05*, s. 37–43.

Těžká forma psoriázy komplikovaná vznikem roztroušené sklerózy, úspěšně léčená ustekinumabem – kazuistika

MUDr. Jiří Ettlér | MUDr. Spyridon Gkalpakiotis, Ph.D., MBA

Dermatovenerologická klinika 3. LF UK a FN KV, Praha

- 1 Nestle, F. O. – Kaplan, D. H. – Barker, J.: Psoriasis. *N Engl J Med*, 2009, 361, s. 496–509.
- 2 Gkalpakiotis, S. – Arenberger, P. – Adenubiová, E.: Psychosociální aspekty života pacientů s psoriázou v České republice. *Čes-slov Derm*, 2013, 4, s. 189–196.
- 3 Schmidt, J. M. – Ford, D. E.: Role of depression in quality of life for patients with psoriasis. *Dermatology*, 2007, 215, s. 17–27.
- 4 Christophers, E.: Comorbidities in psoriasis. *J Eur Acad Dermatol Venerol*, 2006, 20, s. 52–55.
- 5 Cohen, A. D. – Dreier, J. – Birkenfeld, S.: Psoriasis associated with ulcerative colitis and Crohn's disease. *J Eur Acad Dermatol Venerol*, 2009, 23, s. 561–565.
- 6 Tetkovská, P. – Kojanová, M.: Česká doporučení k biologické léčbě závažné chronické ložiskové psoriázy. *Čes-slov Derm*, 2012, 87, s. 1–30.
- 7 Menter, A. – Griffiths, C. E.: Current and future management of psoriasis. *Lancet*, 2007, 370, s. 272–284.
- 8 Van De Kerkhof, P. C.: Novel biologic therapies in development targeting IL-12/IL-23. *J Eur Acad Dermatol*, 2010, 24, s. 5–9.
- 9 Mrowietz, U. – Leopardi, C. L. – Girolomoni, G., et al.: Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). *J Am Acad Dermatol*, 2015, 73, s. 27–36.
- 10 Schmidt, E. – Wetter, D. A. – Ferguson, S. B. – Pittelkow, M. R.: Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor- α inhibitors: the Mayo Clinic experience, 1998 to 2010. *J Am Acad Dermatol*, 2012, 67, s. 179–185.
- 11 Kellner, A. – Dano, M. – Regev, K., et al.: Multiple sclerosis is associated with psoriasis. A case-control study. *J Neurol Sci*, 2014, 338, s. 226–228.
- 12 Kaltsonoudis, E. – Voulgari, P. V. – Konitsiotis, S., et al.: Demyelination and other neurological adverse events after anti-TNF therapy. *Autoimmun Rev*, 2014, 13, s. 54–58.
- 13 Segal, B. M. – Constantinescu, C. S. – Raychaudhuri, A., et al.: Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. *Lancet Neurol*, 2008, 7, s. 796–804.

Vedolizumab v léčbě ulcerózní kolitidy – kazuistika

doc. MUDr. Zuzana Zelinková, Ph.D. IBD Centrum, s. r. o, ASSIDUO, Nemocnica sv. Michala, Bratislava

MUDr. Barbora Kadlečková IBD Centrum, s. r. o, ASSIDUO, Bratislava

- 1 Feagan, B. G., et al.: Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med*, 2013, 369, s. 699–710.
- 2 Mosli, M. H. – MacDonald, J. K. – Bickston, S. J., et al.: Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis. *Inflammatory Bowel Diseases*, 2015, 21, s. 1151–1159.
- 3 Luthra, P. – Peyrin-Biroulet, L. – Ford, A. C.: Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. *Alliment Pharmacol Ther*, 2015, 41, s. 1227–1236.

Možnosti biologické léčby u lupusové nefritidy

prof. MUDr. Romana Ryšavá, CSc. Klinika nefrologie, 1. LF UK a VFN, Praha

- 1 D'Cruz, D. P. – Khamashta, M. A. – Hughes, G. R.: Systemic lupus erythematosus. *Lancet*, 2007, 369, s. 587–596.
- 2 Cervera, R. – Khamashta, M. A. – Hughes, G. R.: The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. *Lupus*, 2009, 18, s. 869–874.
- 3 Wahren-Herlenius, M. – Dörner, T.: Immunopathogenic mechanisms of systemic autoimmune disease. *Lancet*, 2013, 382, s. 819–831.
- 4 Liesnevskaia, L. – Murphy, G. – Isenberg, D.: Systemic lupus erythematosus. *Lancet*, 2014, 384, s. 1878–1888.
- 5 KDIGO Clinical Practice Guidelines for Glomerulonephritis. *Kidney Int Supplements*, 2012, 2, s. 139–274.
- 6 Horák, P. – Tezová, D. – Závada, J., et al.: Doporučení ČRS pro léčbu nemocných se SLE. *Čes Revmatol*, 2013, 21, s. 110–122.
- 7 Kavkaz, H. – Isenberg, D.: Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. *Curr Opin Pharmacol*, 2004, 4, s. 398–402.
- 8 Anolik, J. H. – Campbell, D., et al.: B lymphocyte depletion in the treatment of systemic lupus (SLE): phase I/II trial of rituximab (Rituxan) in SLE. *Arthritis Rheum*, 2002, 46, s. S289.
- 9 Smith, K. G. C. – Jones, R. B. – Burns, S. M. – Jayne, D. R. W.: Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis. *Arthritis Rheum*, 2006, 54, s. 2970–2982.
- 10 Melander, C. – Salope, M. – Trolliet, P., et al.: Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. *CJASN*, 2009, 4, s. 579–587.
- 11 Rovin, B. H. – Fourier, R. – Latinis, K., et al.: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The LUPus Nephritis Assessment with Rituximab (LUNAR) Study. *Arthritis Rheum*, 2012, 64, s. 1215–1226, doi: 10.1002/art.34359, Epub 9. 1. 2012.
- 12 Neuwelt, C. M. – Wallace, D. J., et al.: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. *Arthritis Rheum*, 2010, 62, s. 222–233.
- 13 Díaz-Lagares, C. – Croca, S. – Sangle, S., et al.: Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. *Autoimmun Rev*, 2012, 11, s. 357–364.
- 14 Weidenbusch, M. – Rozmele, C. – Schrötle, A. – Anders, H. J.: Beyond the LUNAR trial: efficacy of rituximab in refractory lupus nephritis. *Nephrol Dial Transplant*, 2013, 28, s. 106–111.
- 15 Wallace, D. J. – Stohl, W. – Furie, R. A., et al.: A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. *Arthritis Rheum*, 2009, 61, s. 1168–1178.
- 16 Navarra, S. V. – Guzman, R. M. – Gallacher, A. E., et al.: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized, placebo-controlled, phase 3 trial. *Lancet*, 2011, 377, s. 721–731.
- 17 Furie, R. A. – Petri, M. – Zamani, O., et al.: A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. *Arthritis Rheum*, 2011, 63, s. 3918–3930.
- 18 Dopleit, M. A. – Houssiau, F. – Aranow, C., et al.: Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. *Lupus*, 2013, 22, s. 63–72.
- 19 Ginzler, E. M. – Wallace, D. J. – Merrill, J. T., et al.: Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. *J Rheumatol*, 2014, 41, s. 300–309.
- 20 Turner-Stokes, T. – Lu, T. Y. – Ehrenstein, M. R., et al.: The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. *Rheumatology (Oxford)*, 2011, 50, s. 1401–1408.
- 21 Rovin, B. H. – Parikh, S. V.: Lupus nephritis: The evolving role of novel therapeutics. *Am J Kidney Dis*, 2014, 63, s. 677–690.

Rituximab v léčbě nefrotického syndromu

prof. MUDr. Vladimír Tesař, DrSc. Klinika nefrologie 1. LF UK a VFN, Praha

- 1 Beck, L. – Bonegio, R. G. – Lambeau, G., et al.: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. *N Engl J Med*, 2009, 361, s. 11–21.
- 2 Beck, L. H., Jr. – Fervenza, F. C. – Beck, D. M., et al.: Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. *J Am Soc Nephrol*, 2011, 22, s. 1543–1550.
- 3 Bech, A. P. – Hofstra, J. M. – Brenchley, P. E., et al.: Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. *Clin J Am Soc Nephrol*, 2014, 9, s. 1386–1392.
- 4 Cattran, D. C. – Reich, H. N. – Beanlands, H. J., et al.: The impact of sex in primary glomerulonephritis. *Nephrol Dial Transplant*, 2008, 23, s. 2247–2253.
- 5 Collier, B. – Lepate, E. – Briere, J., et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse

- large-B-cell lymphoma. *N Engl J Med*, 2002, 346, s. 235–242.
- 6 Cravedi, P. – Remuzzi, G. – Ruggenti, P.: Rituximab in primary membranous nephropathy: first-line therapy, why not? *Nephron Clin Pract*, 2014, 128, s. 261–269.
 - 7 Edwards, J. C. – Szczepanski, L. – Szechinski, J., et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. *N Engl J Med*, 2004, 350, s. 2572–2581.
 - 8 Ferenza, F. C. – Cosio, F. G. – Erickson, S. B., et al.: Rituximab treatment of idiopathic membranous nephropathy. *Kidney Int*, 2008, 73, s. 117–125.
 - 9 Ferenza, F. C. – Abraham, R. S. – Erickson, S. B., et al.: Rituximab treatment in idiopathic membranous nephropathy: a 2-year study. *Clin J Am Soc Nephrol*, 2010, 5, s. 2188–2198.
 - 10 Ferenza, F. C. – Canetta, P. A. – Barbour, S. J., et al.: A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR). *Nephron*, 11. 6. 2015 (epub před tiskem).
 - 11 Fornoni, A. – Sageshima, J. – Wei, C., et al.: Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. *Sci Transl Med*, 2011, 3, s. 85ra46, doi: 10.1126/scitranslmed.3002231.
 - 12 Gregersen, J. W. – Jayne, D. R.: B-cell depletion in the treatment of lupus nephritis. *Nat Rev Nephrol*, 2012, 8, s. 505–514.
 - 13 Guillevin, L. – Pagnoux, C. – Karras, A., et al.: Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. *N Engl J Med*, 2014, 371, s. 1771–1780.
 - 14 Hladunewich, M. A. – Troyanov, S. – Calafati, J., et al.: The natural history of the non-nephrotic membranous nephropathy patient. *Clin J Am Soc Nephrol*, 2009, 4, s. 1417–1422.
 - 15 Hofstra, J. M. – Debiec, H. – Short, C. D., et al.: Antiphospholipase A2 receptor antibody titre and subclass in idiopathic membranous nephropathy. *J Am Soc Nephrol*, 2012, 23, s. 1735–1743.
 - 16 Hogan, S. L. – Muller, K. E. – Jennette, J. C., et al.: A review of therapeutic studies of idiopathic membranous glomerulopathy. *Am J Kidney Dis*, 1995, 25, s. 862–875.
 - 17 Hoxha, E. – Thiele, I. – Zahner, U., et al.: Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. *J Am Soc Nephrol*, 2014, 25, s. 1357–1366.
 - 18 Iijima, K. – Sako, M. – Nozu, K., et al.: Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. *Lancet*, 2014, 384, s. 1273–1281.
 - 19 Kanigicherla, D. – Gummadova, J. – McKenzie, E. A., et al.: Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. *Kidney Int*, 2013, 83, s. 940–948.
 - 20 Korbet, S. M. – Genchi, R. M. – Borok, R. Z., et al.: The racial prevalence of glomerular lesions in nephrotic adults. *Am J Kidney Dis*, 1996, 27, s. 647–651.
 - 21 Kronbichler, A. – Kerschbaum, J. – Fernandez-Fresnedo, G., et al.: Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review. *Am J Nephrol*, 2014, 39, s. 322–330.
 - 22 Magnasco, A. – Ravani, P. – Edefonti, A., et al.: Rituximab in children with resistant idiopathic nephrotic syndrome. *J Am Soc Nephrol*, 2012, 23, s. 1117–1124.
 - 23 Polanco, N. – Gutiérrez, E. – Rivera, F., et al.: Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment. *Nephrol Dial Transplant*, 2012, 27, s. 231–234.
 - 24 Ravani, P. – Rossi, R. – Bonanni, A., et al.: Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. *J Am Soc Nephrol*, 2015, 26, s. 2259–2266.
 - 25 Remuzzi, G. – Chiurciu, C. – Abbate, M., et al.: Rituximab for idiopathic membranous nephropathy. *Lancet*, 2002, 360, s. 923–924.
 - 26 Rood, I. M. – Hofstra, J. M. – Deegens, J. K. J., et al.: B cell suppression in primary glomerular disease. *Adv Chronic Kidney Dis*, 2014, 21, s. 166–181.
 - 27 Rovin, B. H. – Furie, R. – Latinis, K., et al.: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. *Arthritis Rheum*, 2012, 64, s. 1215–1226.
 - 28 Ruggenti, P. – Chiurciu, C. – Abbate, M., et al.: Rituximab for idiopathic membranous nephropathy: who can benefit? *Clin J Am Soc Nephrol*, 2006, 1, s. 738–748.
 - 29 Ruggenti, P. – Cravedi, P. – Chianca, A., et al.: Rituximab in idiopathic membranous nephropathy. *J Am Soc Nephrol*, 2012, 23, s. 1416–1425.
 - 30 Ruggenti, P. – Debiec, H. – Ruggiero, B., et al.: Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. *J Am Soc Nephrol*, 24. 3. 2015, pii: ASN.2014070630 (epub před tiskem).
 - 31 Ruggenti, P. – Ruggiero, B. – Cravedi, P., et al.: Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. *J Am Soc Nephrol*, 2014, 25, s. 850–863.
 - 32 Qin, W. – Beck, L. H., Jr. – Zeng, C., et al.: Anti-phospholipase A2 receptor antibody in membranous nephropathy. *J Am Soc Nephrol*, 2011, 22, s. 1137–1143.
 - 33 Segarra, A. – Praga, M. – Ramos, N., et al.: Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. *Clin J Am Soc Nephrol*, 2009, 4, s. 1083–1088.
 - 34 Schieppati, A. – Mosconi, L. – Perna, A., et al.: Prognosis of untreated patients with idiopathic membranous nephropathy. *N Engl J Med*, 1993, 329, s. 85–89.
 - 35 Stone, J. H. – Merkel, P. A. – Spiera, R., et al.: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med*, 2010, 363, s. 221–232.
 - 36 Svobodova, B. – Honsova, E. – Ronco, P., et al.: Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. *Nephrol Dial Transplant*, 2013, 28, s. 1839–1844.
 - 37 Takie, T. – Itabashi, M. – Moriyama, T., et al.: Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. *Nephrol Dial Transplant*, 2013, 28, s. 1225–1232.
 - 38 Troyanov, S. – Wall, C. A. – Miller, J. A., et al.: Idiopathic membranous nephropathy: definition and relevance of a partial remission. *Kidney Int*, 2004, 66, s. 1199–1205.
 - 39 Yoo, T. H. – Pedigo, C. E. – Guzman, J., et al.: Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. *J Am Soc Nephrol*, 2015, 26, s. 133–147.
 - 40 Ponticelli, C. – Zucchelli, P. – Passerini, P., et al.: A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. *Kidney Int*, 1995, 48, s. 1600–1604.
 - 41 Jha, V. – Ganguli, A. – Saha, T. K., et al.: A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. *J Am Soc Nephrol*, 2007, 18, s. 1899–1904.
 - 42 Praga, M. – Barrio, V. – Juárez, G. F., et al.: Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. *Kidney Int*, 2007, 71, s. 924–930.
 - 43 Howman, A. – Chapman, T. L. – Langdon, M. M., et al.: Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. *Lancet*, 2013, 381, s. 744–751.
 - 44 Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT01508468>, vyhledáno 19. 2. 2016.
 - 45 Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT01180036>, vyhledáno 19. 2. 2016.
 - 46 Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT01955187>, vyhledáno 19. 2. 2016.

Individualizace léčby u roztroušené sklerózy

doc. MUDr. Radomír Taláb, CSc. Neurologická klinika LF UK a FN, Plzeň

- 1 Tintore, M.: Rationale for early intervention with immunomodulatory treatments. *J Neurol*, 2008, 255 (dopl. 1), s. 37–43.
- 2 Kappos, L. – O'Connor, P. W. – Polman, C. H., et al.: Clinical effects of natalizumab on multiple sclerosis: appeal early in treatment course. *J Neurol*, 2013, 260, s. 1388–1395.
- 3 Kinkel, R. P. – Dontchev, M. – Kolman, C., et al.: Association between immediate initiation of intramuscular interferon-beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10 years follow-up if the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. *Arch Neurol*, 2012, 69, s. 183–190.
- 4 Durrelli, L. – Verdun, E. – Barbero, P., et al.: Every-other-day interferon-beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). *Lancet*, 2002, 359, s. 1453–1460.
- 5 Panitch, H. – Goodin, D. S. – Fancic, G., et al.: Randomised, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE trial. *Neurology*, 2002, 59, s. 1496–1506.
- 6 Johnson, K. P. – Brooks, B. R. – Cohen, J. A., et al.: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. *Neurology*, 1995, 45, s. 1268–1276.
- 7 Comi, G. – Filippi, M. – Dolinsky, J. S.: European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. *Ann Neurol*, 2001, 49, s. 290–297.
- 8 Kappos, L. – Freedman, M. S. – Polman, C. H., et al.: for the BENEFIT Study Group. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-years active treatment extension of the phase 3 BENEFIT trial. *Lancet Neurol*, 2009, 8, s. 987–997.
- 9 Jacobs, L. D. – Beck, R. W. – Simon, J. H., et al.: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. *N Engl J Med*, 2000, 343, s. 898–904.
- 10 Comi, G. – Filippi, M. – Barkhof, F., et al.: Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. *Lancet*, 2001, 357, s. 1576–1582.
- 11 Kappos, L. – Polman, C. H. – Freedman, M. S., et al.: Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. *Neurology*, 2006, 67, s. 1242–1249.
- 12 PRISMS (Prevention of Relapses, Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. *Lancet*, 1998, 352, s. 1498–1504.
- 13 Comi, G. – Martinelli, V. – Rodegher, M., et al.: Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISE study): a randomised, double-blind, placebo controlled trial. *Lancet*, 2009, 374, s. 1503–1511.
- 14 Taláb, R. – Talábová, M. – Hofmann, K. L.: Glatiramer acetát a léčba roztroušené sklerózy. *Neurologie praxi*, 2015, 16, s. 231–235.
- 15 Dolinsky, J. S. – Narayana, P. A. – Nelson, F., et al.: Magnetic resonance imaging outcomes from a phase III trial of teriflumidom. *Mult Scler*, 2013, 19, s. 1310–1319.
- 16 Confavreux, C. – O'Connor, P. – Comi, G., et al.: Oral teriflumidom for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Neurol*, 2014, 13, s. 247–256.
- 17 Gold, R. – Kappos, L. – Arnold, D. L., et al.: Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. *N Engl J Med*, 2012, 367, s. 1098–1107.
- 18 Punker, R. A. – Gold, R.: Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects. *Curr Neurol Neurosci Rep*, 2013, 13, s. 394.
- 19 Polman, C. H. – O'Connor, P. W. – Havrdova, E., et al.: A randomised, placebo controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med*, 2006, 354, s. 899–910.
- 20 Sorensen, P. S. – Bertolotto, A. – Edan, G., et al.: Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. *Mult Scler*, 2012, 18, s. 143–152.
- 21 Peter, C. – Ernst-Wilhelm, R., et al.: Efficacy and safety of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS): results from an additional 24-month double-blind, placebo-controlled study (FREEDOMS II study). *Neurology*, 2012, 79, s. E90–E91.
- 22 Cohen, J. A. – Barkhof, F. – Comi, G., et al.: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *N Engl J Med*, 2010, 362, s. 402–415.
- 23 Coles, A. J. – Twyman, C. I. – Arnold, D. I., et al.: Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. *Lancet*, 2012, 380, s. 1829–1839.
- 24 Kappos, L. – Li, D. – Calabresi, P. A., et al.: Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. *Lancet*, 2011, 378, s. 1779–1787.

Alemtuzumab v klinické praxi – kazuistika

MUDr. Eva Meluzínová Neurologická klinika 2. LF UK a FN Motol, Praha

- 1 **Hartung, H. P. – Aktas, O. – Boyko, A. N.:** Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. *Mult Scler*, 2015, 21, s. 22.
- 2 **Coles, A. J. – Twyman, C. L. – Arnold, D. L., et al.:** CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. *Lancet*, 2012, 380, s. 1829–1839, doi: 10.1016/S0140-6736(12)61768-1. Epub 1. 11. 2012, PubMed PMID: 23122650.
- 3 **CAMMS223 Trial Investigators – Coles, A. J. – Compston, D. A. – Selmaj, K. W., et al.:** Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. *N Engl J Med*, 2008, 359, s. 1786–1801.
- 4 **Hoebenaren, I. A. – de Vries, L. C. – Rijnders, R. J. – Lotgering, F. K.:** Delivery of healthy babies after natalizumab use for multiple sclerosis: a report of two cases. *Acta Neurol Scand*, 2011, 123, s. 430–433, doi: 10.1111/j.1600-0404.2010.01426.x, Epub 16. 9. 2010, PubMed PMID: 21492099.
- 5 **Schneider, H. – Weber, C. E. – Hellwig, K., et al.:** Natalizumab treatment during pregnancy—effects on the neonatal immune system. *Acta Neurol Scand*, 2013, 127, s. e1–4, doi: 10.1111/ane.12004, Epub 5. 9. 2012, PubMed PMID: 22950358.
- 6 **Hellwig, K. – Haghikia, A. – Gold, R.:** Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. *Mult Scler*, 2011, 17, s. 958–963, doi: 10.1177/1352458511401944, Epub 25. 5. 2011, PubMed PMID: 21613333.
- 7 **Hu, Y., et al.:** Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. *Immunology*, 2009, 128, s. 260–270.
- 8 **Turner, M. J., et al.:** Immune status following alemtuzumab treatment in human CD52 transgenic mice. *J Neuroimmunol*, 2013, 261, s. 29–36.
- 9 **Cox, A. L., et al.:** Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. *Eur J Immunol*, 2005, 35, s. 3332–3342.
- 10 **Hartung, H. P., et al.:** Lymphocyte subset dynamics following alemtuzumab treatment in the CARE-MS I study. Poster P935,ECTRIMS, Lyon, France, 10.–13. 10. 2012.